|
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer........ |
|
|
Aging: gene silencing or gene activation? |
|
|
Six-week treatment with Ukrain in rabbits. Part III: Serum levels of thyroid hormones |
|
|
Intravenous DMSO – Unsurpassable Results in Clinical Practice |
|
|
The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing |
|
|
Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retar |
|
|
Teratological evaluation of Ukrain in hamsters and rats |
|
|
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. |
|
|
Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. |
|
|
Breast Cancer |
|
|
Evaluation of mutagenic, genotoxic and transforming properties of Ukrain |
|
|
Spike Protein Goes to Nucleus and Impairs DNA Repair (In-Vitro Study) |
|
|
Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort s |
|
|
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative.... |
|
|
Breast Cancer Treatment |
|
|
WITHDRAWN: Multi-agent chemotherapy for early breast cancer. |
|
|
Homeopatic therapy in Cancer Treatment |
|
|
Gemcitabine |
|
|
Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. |
|
|
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhib |
|
|
Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain. |
|
|
Preliminary pharmacokinetic studies of Ukrain in rats |
|
|
PSMA - Lutetium Treatment |
|
|
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) stud |
|
|
Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. |
|
|
Effect of Ukrain on human liver alcohol dehydrogenase activity in vitro. |
|
|
Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carci |
|
|
IV Artesunate |
|
|
Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series |
|
|
Dentists, dental nurses, and brain tumours |
|
|
Removed because of suspicion of scientific fraud: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. |
10.00% |
|
High Dose Intravenous Vitamin C |
10.00% |
|
Herbal Based Cancer Therapies |
10.00% |
|
Clinical aspects of cancer treatment and new biochemical mechanisms of the drug Ukrain. |
20.00% |
|
The immunomodulating preparation Ukrain does not induce anaphylactic sensitization in mice and guinea pigs |
20.00% |
|
Mistletoe as a treatment for cancer. Has no proved benefit, and can cause harm |
20.00% |
|
Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report) |
20.00% |
|
Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. |
20.00% |
|
Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomiz |
25.00% |
|
Bioavailability of sorafenib tablets administered as a liquid suspension. |
30.00% |
|
A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followe |
30.00% |
|
Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. |
30.00% |
|
The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy |
30.00% |
|
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. |
30.00% |
|
Effect of Ukrain on the efficacy of anti-epileptic drugs against maximal electroshock-induced seizures in mice. |
30.00% |
|
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the |
30.00% |
|
Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of m |
30.00% |
|
Pharmacology and safety factors affecting use of flat (rather than weight-based) dosing of tesetaxel, an orally administered.... |
30.00% |
|
Outpatient administration of high-dose methotrexate for osteosarcoma treatment in Brazil. |
30.00% |
|
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated... |
30.00% |
|
Dendritic Cell Therapy |
30.00% |
|
A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillar... |
30.00% |
|
Ukrain: acute toxicity after intravenous, intramuscular and oral administration in rats |
40.00% |
|
Pancreatic cancer stem cells - insights and perspectives. |
40.00% |
|
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. |
40.00% |
|
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. |
40.00% |
|
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. |
40.00% |
|
Serum cytokines in pancreatic cancer: Correlation with outcome |
40.00% |
|
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. |
40.00% |
|
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. |
40.00% |
|
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer. |
40.00% |
|
Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. |
40.00% |
|
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. |
40.00% |
|
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. |
40.00% |
|
Long term outcomes following surgical resection of myxopapillary ependymomas. |
40.00% |
|
Mistletoe in conventional oncological practice: exemplary cases. |
40.00% |
|
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... |
40.00% |
|
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco |
40.00% |
|
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat |
40.00% |
|
In vitro and in vivo antiproliferative activity of laherradurin and cherimolin-2 of Annona diversifolia Saff. |
40.00% |
|
Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated non..... |
40.00% |
|
Ependymoma. |
40.00% |
|
Enhancement of macrophage tumouricidal activity by the alkaloid derivative |
40.00% |
|
Trans Arterial Chemo Embolization(TACE) |
40.00% |
|
Hepatocyte growth factor as inducer of gefitinib resistance in non-small cell lung cancer harboring EGFR activating mutations. |
40.00% |
|
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report) |
40.00% |
|
Inhibition of MIF Leads to Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells. |
40.00% |
|
Melatonin |
45.00% |
|
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr |
45.00% |
|
Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. |
50.00% |
|
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. |
50.00% |
|
Ukrain (NSC-631570) influences on bone status: a review. |
50.00% |
|
Systematic review: Cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. |
50.00% |
|
Ukrain in the treatment of urethral recurrent carcinoma (case report) |
50.00% |
|
Ukrain with chemotherapy in malignant melanoma (case report) |
50.00% |
|
Modification of antinociceptive action of morphine by Ukrain in rodents |
50.00% |
|
Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. |
50.00% |
|
Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, |
50.00% |
|
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung |
50.00% |
|
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin.... |
50.00% |
|
MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in pati |
50.00% |
|
Evaluation of recombinant bacillus Calmette-Guerin expressing pertussis toxin in bladder cancer. |
50.00% |
|
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. |
50.00% |
|
Comparative evaluation of blood plasma and tumor tissue amino acid pool in radiation or neoadjuvant preoperative therapies.... |
50.00% |
|
A study of the influence of a novel drug Ukrain on in vivo effects of low-dose ionizing radiation |
50.00% |
|
Morphometric and kinetic analysis of the growth of experimental sarcoma-45 in the presence of Ukrain |
50.00% |
|
Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus u |
50.00% |
|
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy |
50.00% |
|
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. |
50.00% |
|
Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). |
50.00% |
